Literature DB >> 21603308

Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation.

Luis F Porrata1, Svetomir N Markovic.   

Abstract

The infused stem cell autograft in autologous stem cell transplantation (ASCT) has been viewed mainly as hematologic rescue from the myelosuppressive side effect of conditioning regimens. However, recent reports have shown that the immune effector cells collected at the same time as the stem cells can produce an autologous graft-versus-tumor effect, similar to the graft-versus-tumor effect seen in allogeneic stem cell transplantation without the detrimental effects of graft-versus-host disease. In this article, we review the different immune effector cells collected and infused from the stem cell autograft and their association with clinical outcome post-ASCT, suggesting that ASCT can be viewed not only as a therapeutic maneuver to recover bone marrow function after deliver high-dose chemotherapy, but also as an adoptive immunotherapeutic intervention capable of eradicating residual tumor cells in patients with cancer.

Entities:  

Keywords:  Adoptive immunotherapy; Autograft; Autologous graft versus tumor effect

Year:  2010        PMID： 21603308      PMCID： PMC3095451          DOI： 10.5306/wjco.v1.i1.29

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN： 2218-4333


  36 in total

1.  Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.

Authors:  L F Porrata; J N Ingle; M R Litzow; S Geyer; S N Markovic
Journal:  Bone Marrow Transplant       Date:  2001-11       Impact factor: 5.483

Review 2.  The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation.

Authors:  D L Porter
Journal:  J Hematother Stem Cell Res       Date:  2001-08

3.  Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.

Authors:  L F Porrata; M A Gertz; D J Inwards; M R Litzow; M Q Lacy; A Tefferi; D A Gastineau; A Dispenzieri; S M Ansell; I N Micallef; S M Geyer; S N Markovic
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

4.  Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease.

Authors:  Luis F Porrata; David J Inwards; Ivana N Micallef; Stephen M Ansell; Susan M Geyer; Svetomir N Markovic
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

Review 5.  Natural killer cells and dendritic cells: rendezvous in abused tissues.

Authors:  Alessandro Moretta
Journal:  Nat Rev Immunol       Date:  2002-12       Impact factor: 53.106

Review 6.  Haematopoietic cell transplantation as immunotherapy.

Authors:  F R Appelbaum
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

7.  Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.

Authors:  J A Sosman; P Stiff; S M Moss; P Sorokin; B Martone; R Bayer; K van Besien; S Devine; W Stock; D Peace; Y Chen; C Long; D Gustin; M Viana; R Hoffman
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

8.  Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.

Authors:  A K Stewart; R Vescio; G Schiller; O Ballester; S Noga; H Rugo; C Freytes; E Stadtmauer; S Tarantolo; F Sahebi; P Stiff; J Meharchard; R Schlossman; R Brown; H Tully; M Benyunes; C Jacobs; R Berenson; M White; J DiPersio; K C Anderson; J Berenson
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

9.  Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.

Authors:  J Parrish-Novak; S R Dillon; A Nelson; A Hammond; C Sprecher; J A Gross; J Johnston; K Madden; W Xu; J West; S Schrader; S Burkhead; M Heipel; C Brandt; J L Kuijper; J Kramer; D Conklin; S R Presnell; J Berry; F Shiota; S Bort; K Hambly; S Mudri; C Clegg; M Moore; F J Grant; C Lofton-Day; T Gilbert; F Rayond; A Ching; L Yao; D Smith; P Webster; T Whitmore; M Maurer; K Kaushansky; R D Holly; D Foster
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

10.  Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders.

Authors:  A Ackerstein; E Kedar; S Slavin
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113
View more
  2 in total

1.  Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation.

Authors:  A Kansagra; D J Inwards; S M Ansell; I N Micallef; P B Johnston; W J Hogan; S N Markovic; L F Porrata
Journal:  Bone Marrow Transplant       Date:  2017-10-16       Impact factor: 5.483

Review 2.  Autologous Graft-versus-Tumor Effect: Reality or Fiction?

Authors:  Luis F Porrata
Journal:  Adv Hematol       Date:  2016-08-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.